Evolus, Inc. (EOLS): Price and Financial Metrics
GET POWR RATINGS... FREE!
EOLS POWR Grades
- EOLS scores best on the Growth dimension, with a Growth rank ahead of 70.66% of US stocks.
- EOLS's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
- EOLS ranks lowest in Stability; there it ranks in the 5th percentile.
EOLS Stock Summary
- Equity multiplier, or assets relative to shareholders' equity, comes in at 8.98 for Evolus Inc; that's greater than it is for 89.02% of US stocks.
- With a year-over-year growth in debt of -75.76%, Evolus Inc's debt growth rate surpasses only 4.34% of about US stocks.
- In terms of volatility of its share price, EOLS is more volatile than 89.16% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Evolus Inc are MCB, ASRT, RMCF, CWST, and REED.
- EOLS's SEC filings can be seen here. And to visit Evolus Inc's official web site, go to www.evolus.com.
EOLS Valuation Summary
- EOLS's EV/EBIT ratio is -3.8; this is 112.97% lower than that of the median Healthcare stock.
- Over the past 43 months, EOLS's price/sales ratio has gone NA NA.
- Over the past 43 months, EOLS's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for EOLS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EOLS | 2021-08-31 | 7.6 | 5.5 | -4.4 | -3.8 |
| EOLS | 2021-08-30 | 7.5 | 5.4 | -4.4 | -3.8 |
| EOLS | 2021-08-27 | 7.6 | 5.5 | -4.5 | -3.8 |
| EOLS | 2021-08-26 | 7.7 | 5.5 | -4.5 | -3.8 |
| EOLS | 2021-08-25 | 7.9 | 5.7 | -4.6 | -4.0 |
| EOLS | 2021-08-24 | 7.9 | 5.7 | -4.6 | -4.0 |
EOLS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EOLS has a Quality Grade of C, ranking ahead of 48.49% of graded US stocks.
- EOLS's asset turnover comes in at 0.373 -- ranking 126th of 677 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows EOLS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.373 | 0.630 | -3.772 |
| 2021-03-31 | 0.300 | 0.674 | -1.580 |
| 2020-12-31 | 0.271 | 0.676 | -1.214 |
| 2020-09-30 | 0.256 | 0.735 | -0.356 |
| 2020-06-30 | 0.245 | 0.734 | -0.491 |
| 2020-03-31 | 0.216 | 0.731 | -0.603 |
EOLS Price Target
For more insight on analysts targets of EOLS, see our EOLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $17.14 | Average Broker Recommendation | 1.57 (Moderate Buy) |
EOLS Stock Price Chart Interactive Chart >
EOLS Price/Volume Stats
| Current price | $8.09 | 52-week high | $17.38 |
| Prev. close | $7.95 | 52-week low | $2.85 |
| Day low | $7.89 | Volume | 552,700 |
| Day high | $8.23 | Avg. volume | 985,892 |
| 50-day MA | $10.19 | Dividend yield | N/A |
| 200-day MA | $9.72 | Market Cap | 441.52M |
Evolus, Inc. (EOLS) Company Bio
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is based in Irvine, California.
Latest EOLS News From Around the Web
Below are the latest news stories about Evolus Inc that investors may wish to consider to help them evaluate EOLS as an investment opportunity.
Evolus Announces Participation in September Investment ConferencesNEWPORT BEACH, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two investment conferences in September. |
4 Stocks Insiders Are BuyingWhen insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Evolus The Trade: Evolus |
When Will Evolus, Inc. (NASDAQ:EOLS) Become Profitable?Evolus, Inc. ( NASDAQ:EOLS ) is possibly approaching a major achievement in its business, so we would like to shine... |
Evolus Reports Second Quarter 2021 Results and Provides Business UpdateRecord Quarter: Net Revenue Grew 235% Year-over-Year to $26.1 Million |
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue EstimatesEvolus, Inc. (EOLS) delivered earnings and revenue surprises of -12.50% and 2.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? |
EOLS Price Returns
| 1-mo | -27.05% |
| 3-mo | -39.40% |
| 6-mo | -31.27% |
| 1-year | 117.47% |
| 3-year | -55.20% |
| 5-year | N/A |
| YTD | 140.77% |
| 2020 | -72.39% |
| 2019 | 2.27% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching EOLS
Want to see what other sources are saying about Evolus Inc's financials and stock price? Try the links below:Evolus Inc (EOLS) Stock Price | Nasdaq
Evolus Inc (EOLS) Stock Quote, History and News - Yahoo Finance
Evolus Inc (EOLS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...